Overview

Efficacy and Safety in a Randomised Acute Pain Study of MR308 (Tramadol/Celecoxib).

Status:
Completed
Trial end date:
2018-01-04
Target enrollment:
Participant gender:
Summary
The MR308-3501 study is a multicenter, randomised, double-blind, parallel-group study in male and female adult subjects to demonstrate the efficacy of MR308 in the treatment of acute moderate to severe pain after the extraction of at least two third molars requiring bone removal.
Phase:
Phase 3
Details
Lead Sponsor:
Mundipharma Research GmbH & Co KG
Treatments:
Celecoxib
Tramadol